$RCKT Stock Is up 3% Today. Here's What We See in Our Data.
Is Rocket Pharmaceuticals (NASDAQ:RCKT) In A Good Position To Deliver On Growth Plans?
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
Top Executive Makes Bold Move With Major Stock Purchase in Rocket Pharmaceuticals
Needham Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $42
Express News | Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $42 Price Target
Strategic Positioning and Growth Potential: Buy Rating for Rocket Pharmaceuticals
BMO Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $50
Rocket Pharmaceuticals CFO Makes Significant Stock Sale!
Insider Sale: Chief Financial Officer of $RCKT Sells 7,489 Shares
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) Path To Profitability
Rocket Pharmaceuticals Down Over 14%, on Track for Lowest Close Since September 2017 -- Data Talk
How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks
Cantor Fitzgerald Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $50
BMO Capital Initiates Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Announces Target Price $50
BMO Capital Initiates Coverage On Rocket Pharmaceuticals With Outperform Rating, Announces Price Target of $50
Rocket Pharmaceuticals Price Target Cut to $36.00/Share From $39.00 by Canaccord Genuity
Rocket Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $36